• GENB share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • Price change

    The price of GENB shares has increased $0.03 since the market last closed. This is a 0.23% rise.

  • Closed at $13.12.

    The stock has since risen $0.19 in after-hours trading.

Key terms

About GENB

Generate Biomedicines, Inc. is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company was founded in 2018, and is headquartered in Somerville, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
  • Market cap: $1.68B

    A market capitalization between $300 million and $2 billion places GENB in the small capitalization category.

Key terms

Smart score

Latest GENB news

May 14, 2026 12:37pm ET Generate Biomedicines price target raised to $22 from $20 at Morgan Stanley by TipRanks May 14, 2026 11:16am ET Generate Biomedicines, Inc. (GENB) Receives a Buy from Morgan Stanley by TipRanks May 08, 2026 8:59am ET Piper Sandler Sticks to Their Buy Rating for Generate Biomedicines, Inc. (GENB) by TipRanks May 08, 2026 6:32am ET Generate Biomedicines price target raised to $25 from $16 at H.C. Wainwright by TipRanks May 07, 2026 7:16am ET Generate Biomedicines reports Q1 revenue $7.22M, consensus $4.75M by TipRanks Apr 13, 2026 6:18am ET Generate Biomedicines initiated with a Buy at H.C. Wainwright by TipRanks Apr 10, 2026 1:45pm ET Buy Rating on Generate Biomedicines Driven by Differentiated Pipeline, GB-0895 Asthma Opportunity, and AI-Enabled Protein Platform by TipRanks Mar 24, 2026 7:56am ET Generate Biomedicines initiated with an Overweight at Cantor Fitzgerald by TipRanks Mar 24, 2026 6:25am ET Generate Biomedicines initiated with an Overweight at Cantor Fitzgerald by TipRanks Mar 24, 2026 5:15am ET Generate Biomedicines initiated with a Buy at Guggenheim by TipRanks Mar 24, 2026 5:10am ET Generate Biomedicines initiated with an Overweight at Morgan Stanley by TipRanks Mar 24, 2026 5:00am ET Generate Biomedicines initiated with an Overweight at Piper Sandler by TipRanks Mar 24, 2026 4:35am ET Generate Biomedicines initiated with a Buy at Goldman Sachs by TipRanks Mar 23, 2026 11:30am ET Opening Day: Janus Living opens at $23.50 after upsized IPO by TipRanks Mar 06, 2026 9:07pm ET Top Executive Makes Bold Insider Bet on Biotech Future by TipRanks Mar 02, 2026 9:05pm ET Massive Insider Buying Spree Sends Strong Signal at Generate Biomedicines by TipRanks Mar 02, 2026 11:30am ET Opening Day: Generate Biomedicines makes public debut by TipRanks Feb 27, 2026 12:55pm ET Generate Biomedicines opens at $15.00, IPO priced at $16.00 by TipRanks Feb 27, 2026 12:40pm ET Generate Biomedicines opens at $15.00, IPO priced at $16.00 by TipRanks Feb 26, 2026 8:05pm ET Generate Biomedicines 25M share IPO priced at $16.00 by TipRanks

No recent press releases are available for GENB

GENB Financials

1-year income & revenue

  • GENB total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • GENB net income: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • GENB earnings per share: currently unavailable. Sorry, we currently don't have enough data to create an insight.

Key terms

GENB Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

GENB Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range
  • How competitors are chosen

    GENB's competitors are included in the Health Technology sector and Biotechnology group

  • Market cap: $1.68B

    A market capitalization between $300 million and $2 billion places GENB in the small capitalization category.

Key terms

Latest investing news